**AGP: Adjustment of the Report on the results of issuing shares to pay dividends in 2023**

On May 03, 2024, Agimexpharm Pharmaceutical Joint Stock Company announced Official Dispatch No. 04/CV-AGP on adjusting the Report on the results of issuing shares to pay dividends in 2023 as follows:

|  |  |  |
| --- | --- | --- |
| **Content** | **Before adjustment** | **After adjustment** |
| 1. Report on results of share issuance to pay dividends in 2023 | * Report No. 04/BC-AGP dated April 24, 2024. * Section 1, Part III:   Total number of distributed shares: 2,479,488 shares, in which:  Number of shares distributed to shareholders according to the rate: 2,479,488 shares for 780 shareholders;  Number of fractional shares handled: 0 shares. | * Report No. 05/BC-AGP dated April 26, 2024. * Section 1, Part III:   Total number of distributed shares: 2,479,488 shares, in which:  Number of shares distributed to shareholders according to the rate: 2,479,488 shares for 780 shareholders;  Number of fractional shares handled (canceled): 246 shares. |
| 2. Notice on changing the number of shares with voting rights | Notice No. 05/TB-AGP dated April 24, 2024 | Notice No. 06/TB-AGP dated April 26, 2024 |

*Reason: Mistake in fractional shares*

On April 26, 2024, Agimexpharm Pharmaceutical Joint Stock Company announced Report No. 05/BC-AGP on the results of issuing shares to pay dividends in 2023 as follows:

1. Plan on share issuance to pay dividends
2. Share name: Shares of Agimexpharm Pharmaceutical Joint Stock Company
3. Share type: Common share
4. Number of shares before issuance:

* Total number of issued shares: 20,664,453 shares
* Number of outstanding shares: 20,664,453 shares
* Number of treasury shares: 0 shares

1. Number of shares expected to be issued: 2,479,734 shares
2. Rights exercise rate: 100:12, shareholders owning 01 share will receive 01 rights to receive additional shares. For every 100 rights to receive additional shares, shareholders will receive 12 new shares.
3. Capital source for the issuance: Undistributed profit after tax. The value of undistributed profit after tax is determined as of December 31, 2023, according to the Audited Financial Statements 2023 of Agimexpharm Pharmaceutical Joint Stock Company.
4. Plan on handling fractional shares: The number of additional shares will be rounded down to the unit, and the decimal part (if any) will be canceled

*For example: Shareholder A owns 128 shares at the record date for the list of shareholders. With the rights exercise rate of 100:12, shareholder A will receive (128/100 \* 12) = 15.36 new shares. According to the above calculation principle, shareholder A will receive 15 new shares. 0.36 fractional shares will be canceled.*

1. End date of the issuance: April 19, 2024.
2. Expected date to transfer shares: In May and June 2024.
3. Results of issuing shares to pay dividends
4. Total number of distributed shares: 2,479,488 shares, in which:

* Number of shares distributed to shareholders according to the rate: 2,479,488 shares for 780 shareholders;
* Number of fractional shares handled (canceled): 246 shares.

1. Total number of shares after issuance (April 24, 2024): 23,143,941 shares, in which:

* Number of outstanding shares: 23,143,941 shares;
* Number of treasury shares: 0 shares.